Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

HER2-positive Breast Cancer 1 Adenocarcinoma Of Esophagus 1

Interventions

Trastuzumab 3 pertuzumab 2 Docetaxel 2 tucatinib 1 Protons 1 Paclitaxel 1 Carboplatin 1 Capecitabine 1 ARX788 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × HER2-positive Breast Cancer × tucatinib × Clear all

NCT07413939 2026-05-11

BREnnA

Hoffmann-La Roche

Phase 2/3 Recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡